Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has earned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $63.73.

Several equities analysts recently weighed in on IMCR shares. JPMorgan Chase & Co. dropped their price objective on Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. Mizuho cut their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research report on Monday, April 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently modified their holdings of IMCR. Hennion & Walsh Asset Management Inc. increased its position in Immunocore by 26.1% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 62,555 shares of the company’s stock worth $1,856,000 after purchasing an additional 12,947 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Immunocore by 3,318.1% in the first quarter. GAMMA Investing LLC now owns 19,107 shares of the company’s stock worth $5,670,000 after acquiring an additional 18,548 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Immunocore in the 4th quarter valued at $4,868,000. GF Fund Management CO. LTD. purchased a new position in shares of Immunocore in the 4th quarter valued at $25,000. Finally, Woodline Partners LP lifted its holdings in shares of Immunocore by 19.4% during the 4th quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock valued at $9,678,000 after acquiring an additional 53,378 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Up 1.2 %

Shares of NASDAQ IMCR opened at $26.92 on Tuesday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a 50-day moving average price of $28.86 and a 200 day moving average price of $30.46. Immunocore has a 52 week low of $23.15 and a 52 week high of $62.74. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -28.34 and a beta of 0.75.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.